Novo Nordisk A/S

🇩🇰Denmark

Country: 🇩🇰Denmark

Ownership: Public

Established: 1923-01-01

Employees: 63.3K

Market Cap: $602.2B

Website: http://www.novonordisk.com

Clinical Trials

A Trial to Investigate Different Needle Features Assessed by Comparing Insulin Aspart Pharmacokinetic Profiles

Phase 1

Completed

Conditions: Diabetes

Interventions: Drug: insulin aspart

First Posted Date: 2015-11-01

Last Posted Date: 2017-08-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 46

Registration Number: NCT02594033

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Comparing Efficacy and Safety of Thrice Daily Versus Twice Daily NovoMix® 30 (Biphasic Insulin Aspart 30) in Subjects With Type 2 Diabetes Inadequately Controlled With Basal Insulin

Phase 4

Completed

Conditions: Diabetes
Type 2 Diabetes Mellitus

Interventions: Drug: biphasic insulin aspart 30

First Posted Date: 2015-10-21

Last Posted Date: 2019-06-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 437

Registration Number: NCT02582242

Locations: 🇺🇦
Novo Nordisk Investigational Site, Ternopil, Ukraine

Validation of Two Measures for Growth Hormone Deficiency in Children, the Treatment Related Impact Measure of Childhood Growth Hormone Deficiency (TRIM-CGHD) and the Treatment Burden Measure of Childhood Growth Hormone Deficiency (TB-CGHD)

Completed

Conditions: Growth Disorder
Growth Hormone Deficiency in Children

Interventions: Other: No treatment given

First Posted Date: 2015-10-20

Last Posted Date: 2020-09-25

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 252

Registration Number: NCT02580032

Locations: 🇬🇧
Novo Nordisk Investigational Site, Manchester, United Kingdom

Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S)

Completed

Conditions: Haemostasis
Haemophilia B
Congenital Bleeding Disorder

Interventions: Other: No treatment given

First Posted Date: 2015-10-05

Last Posted Date: 2016-01-12

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 449

Registration Number: NCT02568202

Locations: 🇺🇸
Novo Nordisk Clinical Trial Call Center, Plainsboro, New Jersey, United States

Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: Faster-acting insulin aspart
Drug: insulin aspart

First Posted Date: 2015-10-05

Last Posted Date: 2018-12-11

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 42

Registration Number: NCT02568280

Locations: 🇦🇹
Novo Nordisk Investigational Site, Graz, Austria

A First Human Dose Trial Investigating Safety, Tolerability and Pharmacokinetics for Single Doses and Multiple Doses of NNC0165-1562 in Overweight to Obese But Otherwise Healthy Subjects

Phase 1

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: NNC0165-1562

First Posted Date: 2015-10-05

Last Posted Date: 2018-07-13

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 93

Registration Number: NCT02568306

Locations: 🇺🇸
Novo Nordisk Investigational Site, Tempe, Arizona, United States

Comparing Semaglutide Administered Subcutaneously Once Daily to Semaglutide Administered Subcutaneously Once Weekly

Phase 1

Completed

Conditions: Diabetes
Healthy

Interventions: Drug: semaglutide
Drug: placebo

First Posted Date: 2015-09-23

Last Posted Date: 2017-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 113

Registration Number: NCT02557620

Locations: 🇩🇪
Novo Nordisk Investigational Site, Berlin, Germany

Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial

Phase 2

Completed

Conditions: Haemophilia A With Inhibitors
Congenital Bleeding Disorder
Haemophilia B With Inhibitors

Interventions: Other: No treatment given

First Posted Date: 2015-09-04

Last Posted Date: 2019-01-04

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 19

Registration Number: NCT02541942

Locations: 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand

Comparing Pharmacodynamic and Pharmacokinetic Properties of Insulin Degludec and Insulin Glargine 300 U/mL at Steady-state Conditions in Subjects With Type 1 Diabetes Mellitus

Phase 1

Completed

Conditions: Diabetes
Diabetes Mellitus, Type 1

Interventions: Drug: insulin degludec
Drug: insulin glargine

First Posted Date: 2015-09-01

Last Posted Date: 2019-05-01

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 60

Registration Number: NCT02536859

Locations: 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany

Effect of Liraglutide for Weight Management in Paediatric Subjects With Prader-Willi Syndrome

Phase 3

Completed

Conditions: Metabolism and Nutrition Disorder
Obesity

Interventions: Drug: placebo
Drug: liraglutide

First Posted Date: 2015-08-18

Last Posted Date: 2023-07-06

Lead Sponsor: Novo Nordisk A/S

Target Recruit Count: 56

Registration Number: NCT02527200

Locations: 🇹🇷
Novo Nordisk Investigational Site, Trabzon, Turkey

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy